ACM
PTGX icon

Aquatic Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Aquatic Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,615
Closed -$3.2M – 1725
2025
Q4 		$3.2M Buy
+36,615
New +$3M 0.09% 272
2025
Q3 		– Sell
-42,000
Closed -$2.32M – 1609
2025
Q2 		$2.32M Buy
42,000
+26,893
+178% +$1.29M 0.05% 437
2025
Q1 		$731K Buy
+15,107
New +$633K 0.02% 677
2024
Q2 		– Sell
-2,300
Closed -$66.5K – 1526
2024
Q1 		$66.5K Sell
2,300
-6,400
-74% -$174K ﹤0.01% 992
2023
Q4 		$199K Buy
8,700
+200
+2% +$3.5K 0.01% 848
2023
Q3 		$142K Buy
8,500
+7,400
+673% +$144K 0.01% 756
2023
Q2 		$30K Buy
+1,100
New +$27.5K ﹤0.01% 1073
2023
Q1 		– Sell
-22,300
Closed -$243K – 1665
2022
Q4 		$243K Buy
+22,300
New +$188K 0.02% 698

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Aquatic Capital Management's PTGX Position: Q1 2026 in Review

Aquatic Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 36,615 shares — an estimated $3.2M sold.

Aquatic Capital Management first reported a position in PTGX in Q4 2022 and held it in 8 quarters. The position peaked at $3.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Aquatic Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 36,615 Protagonist Therapeutics shares in Q1 2026, an estimated $3.2M.
  • Aquatic Capital Management first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 8 quarters.
  • Aquatic Capital Management's Protagonist Therapeutics position peaked at $3.2M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.